Modern Meadow is a technology company.
Modern Meadow has raised $184.0M across 4 funding rounds.
Modern Meadow has raised $184.0M in total across 4 funding rounds.
Modern Meadow is a sustainable bio-design technology company that develops animal-free, biofabricated leather alternatives and protein-based materials using synthetic biology and nature-inspired proteins.[2][3] It builds Bio-Alloy™, Bio-F@rm™, and Bio-Coll@gen™ technology platforms, which create high-performance biomaterials like collagen for industries including fashion, footwear, automotive, textiles, personal care, and biomedical.[2][4][5] These solutions serve visionary brands and manufacturers seeking sustainable alternatives to petrochemical and animal-derived inputs, solving problems of environmental impact—such as 95% less water use, 75-80% less energy and chemicals—while delivering superior durability, breathability, abrasion resistance, and scalability through "drop-in" compatibility with existing global manufacturing.[3][5][6] The company demonstrates growth momentum via industry partnerships, a $53M Series B raise, and recognition like Fast Company's 2022 Innovation by Design finalist status across three categories.[1][7]
Founded in 2011 by Andras Forgacs and others with a mission to reimagine materials, sustainability, and consumption by replacing animal-derived and petrochemical-based inputs with nature-inspired alternatives.[3][5] The idea emerged from early tissue engineering efforts in a small lab to produce leather-like materials, evolving into a full biofabrication platform using DNA editing tools, yeast fermentation, and precision protein design.[4] Pivotal moments include expanding from leather alternatives to broader platforms like Bio-Alloy™ (a miscible plant-protein and bio-polymer blend) and Bio-F@rm™ for scalable protein production, with early traction through partnerships and tech transfers to manufacturing.[3][5][6] Leadership transitions, such as David Williamson as CTO and Catherine Roggero-Lovisi as CEO, have driven this shift toward commercial scalability.[4][7]
Modern Meadow stands out through proprietary, drop-in technologies that integrate seamlessly into existing infrastructure, enabling rapid adoption without high costs or retooling.[2][3][6]
Modern Meadow rides the synthetic biology and biofabrication wave, addressing climate-driven demands for circular materials amid leather industry shortages and petrochemical scrutiny.[2][3][8] Timing aligns with global sustainability regulations, rising consumer preference for ethical products, and synbio advancements in precision fermentation, enabling cost-competitive scaling.[4][5] Market forces like supply chain disruptions and ESG pressures favor its drop-in model, blurring lines between biotech, materials science, and consumer goods while fostering industry convergence.[1][3] It influences the ecosystem by setting benchmarks for protein-enabled dyeing (Bio-Shield™), reducing reliance on animal agriculture, and partnering to accelerate bio-based supply chains, catalyzing widespread adoption in fashion and beyond.[6][7][8]
Modern Meadow is poised to expand its protein platforms into high-volume applications like automotive and biomedical, leveraging partnerships for global scale and new formulations via ongoing R&D in AI and ecosystem connectivity.[1][5] Trends like regulatory pushes for PFAS bans, synbio cost reductions, and luxury brand sustainability mandates will propel growth, potentially amplifying its $53M-funded momentum toward market leadership.[1][7] Its influence may evolve from leather pioneer to materials powerhouse, redefining bio-alloys as standard for performance-driven sustainability—transforming biotech from niche to industry norm, much like its founding vision to build a greener world through scalable innovation.[2][3]
Modern Meadow has raised $184.0M in total across 4 funding rounds.
Modern Meadow's investors include Astanor Ventures, B Capital Group, Jacob Conger, iNovia Capital, Panache Ventures, Preface Ventures, Stellar Capital, Talis Capital, Tribe Capital, Bart Swanson, Moshe Lifschitz, Ron Pragides.
Modern Meadow has raised $184.0M across 4 funding rounds. Most recently, it raised $130.0M Series C in April 2021.